Making decisive change.

With all the continuity – recent developments prove that Merck has the key to creating something fundamentally new at the right moment. The integration of the biopharmaceutical company Serono creates potential for more: The best of both Merck and Serono is converging and cross-pollinating. Merck has the courage and the strength to pursue new avenues in pharmaceutical research with a research and development budget that has nearly doubled. We are working to discover and develop new active ingredients, especially for oncology, neurodegenerative diseases, autoimmune and inflammatory diseases, and fertility. A new organizational structure has enabled us to streamline our development and decision-making processes and clarify the prospects for the success of new active ingredients and technologies at a very early stage. In the future, new developments will happen faster, not only in the laboratory, but also in logistics, service and production. We’re strong on the execution side, also when it comes to strategic changes – as the rapid divestment of the Generics division in 2007 showed.